Cromos Pharma
Share
As Memorial Day weekend begins, Cromos Pharma takes a moment to honor and remember the brave men and women who gave their lives in service to their country.
We sincerely thank them for their sacrifice, courage, and dedication. Wishing everyone a safe and meaningful holiday weekend.
05/07/2026
In the latest edition of Cromos Pharma’s Newsletter, we highlight key developments shaping clinical research in 2026:
– FDA Transparency Pressure: More than 2,200 sponsors were flagged over missing trial results, highlighting growing scrutiny around data reporting and clinical transparency.
– Rare Disease Innovation: EMA recommended approval of plozasiran, a first in class siRNA therapy for familial chylomicronaemia syndrome with significant reductions in triglycerides and pancreatitis risk.
– A Potential Breakthrough in Pancreatic Cancer: Daraxonrasib Phase III data demonstrated one of the most meaningful survival advances seen in pancreatic cancer in decades.
Read the full newsletter: https://cromospharma.com/clinical-research-focus-52nd-edition/
Cromos Pharma is currently seeking an In-house CRA to join our team.
Location: Europe
For additional details about this opportunity, please visit our website: https://cromospharma.com/in-house-cra/
If you're ready to apply, please send your CV to [email protected]
Click here to claim your Sponsored Listing.
Telephone
Website
Address
US Bancorp Tower, 111 S. W. Fifth Avenue, Suite 3150
Portland, OR
97204
